Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2017 > Exploratory Oncology Research & Clinical Trial Center

Annual Report 2017

Division of Innovative Pathology and Laboratory Medicine (Kashiwa Campus)

Takeshi Kuwata, Masato Sugano, Shigeyuki Hasuo, Shigeo Yoshida, Yuko Iwata

Introduction

 The Division of Innovative Pathology and Laboratory Medicine (IPLM) was newly established in the Exploratory Oncology Research and Clinical Trial Center (EPOC) in 2016. The aim of the IPLM is to develop new diagnostic technologies, reagents, and devices in pathology and laboratory medicine field.

Our team and what we do

 To achieve our goal, the activities of the IPLM are closely collaborated with the Department of Pathology and Clinical Laboratories in the National Cancer Center Hospital East (NCCHE) and the Division of Pathology as well as other divisions in the EPOC.

Figure 1. Schema of DEF study
Figure 1. Schema of DEF study

Figure 1. Schema of DEF study
Figure 1. Schema of DEF study(Full Size)


Figure 2. Pathological features of PDX
Figure 2.  Pathological features of PDX

Figure 2. Pathological features of PDX
Figure 2.  Pathological features of PDX(Full Size)

Research activities

 We are conducting the DEF (Discovery and Establishment of new biomarkers For gastric cancer) study, in which patient-derived xenografts (PDX) and cell lines have been established from surgically resected gastric cancers as well ascites. The aim of this study is to establish reliable bio-resources for supporting activities of new drug development in academia as well as pharmaceuticals. By March 2018, we have successfully established a total of 37 gastric cancer PDXs and 31 novel gastric cancer cell lines. The expression of selected receptor tyrosine-kinases, HER2, EGFR and MET, has been evaluated in all PDX models. NGS-based gene mutation profiles are also added in some PDX models.

Education

 We are participating in a weekly clinical conference with the Department of Pathology and Clinical Laboratories in the NCCHE. We also hold a biweekly progress research meeting in the EPOC as well as a monthly research meeting with the Division of Pathology in the EPOC. We presented our research data in scientific meetings including an annual meeting of the Japanese Society of Pathology and have published in well-recognized scientific journals.

Future prospects

 Our goal is to develop new diagnostic technologies, reagents and devices required for providing precision medicine to all cancer patients. For this purpose we will use our experiences at the NCCHE and conduct translational/reverse- translational researches. In collaboration with the Department of Pathology and Clinical Laboratories, we will also conduct a genetic testing division and provide clinical sequence service in the NCCHE.